カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

ヒトマイクロバイオームの世界市場予測（〜2029年）：製品別、用途別、疾患別、種類別

◆英語タイトル：Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

MarketsandMarketsが発行した調査報告書（BT2711-23）◆商品コード：BT2711-23
◆発行会社（リサーチ会社）：MarketsandMarkets
◆発行日：2023年5月26日
◆ページ数：183
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：バイオ
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

MarketsandMarkets社の本調査レポートでは、世界のヒトマイクロバイオーム市場規模が2023年の3億ドルから2029年までに17億ドルに拡大し、予測期間中に年平均36.1%で成長すると予想しています。本書では、ヒトマイクロバイオームの世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、用途別（治療薬、診断薬）分析、疾患別（感染症、胃腸疾患、内分泌・代謝疾患、がん、その他）分析、製品別（薬剤、診断検査、プロバイオティクス、プレバイオティクス、その他）分析、種類別（細菌コンソーシアム移植（Bct）/糞便微生物叢移植（FMT）、ペプチド、ライブバイオセラピー製品、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他地域）分析、競争状況、企業情報などの内容を掲載しています。また、参入企業情報として、Seres TherapeuticsInc.（US）、Enterome（France）、4D pharma plc（UK）、International Flavors & Fragrances Inc.（US）などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のヒトマイクロバイオーム市場規模：用途別
- 治療薬における市場規模
- 診断薬における市場規模
・世界のヒトマイクロバイオーム市場規模：疾患別
- 感染症における市場規模
- 胃腸疾患における市場規模
- 内分泌・代謝疾患における市場規模
- がんにおける市場規模
- その他疾患における市場規模
・世界のヒトマイクロバイオーム市場規模：製品別
- 薬剤の市場規模
- 診断検査の市場規模
- プロバイオティクスの市場規模
- プレバイオティクスの市場規模
- その他製品の市場規模
・世界のヒトマイクロバイオーム市場規模：種類別
- 細菌コンソーシアム移植（Bct）/糞便微生物叢移植（FMT）の市場規模
- ペプチドの市場規模
- ライブバイオセラピー製品の市場規模
- その他種類の市場規模
・世界のヒトマイクロバイオーム市場規模：地域別
- 北米のヒトマイクロバイオーム市場規模
- ヨーロッパのヒトマイクロバイオーム市場規模
- アジア太平洋のヒトマイクロバイオーム市場規模
- その他地域のヒトマイクロバイオーム市場規模
・競争状況
・企業情報

“ヒトマイクロバイオーム市場は、予測期間中の年平均成長率36.1%で、2023年の3億米ドルから2029年には17億米ドルに達すると予測”
ヒトマイクロバイオーム市場の成長を促進する主な要因として、個別化医療に対する需要の急増であり、自然でホリスティックなアプローチに対する需要の高まりが市場の成長を促進すると期待されています。しかし、微生物の相互作用に関する理解は限られているため、市場の成長はある程度抑制されると予想されます。ヒトマイクロバイオーム市場は、製品、タイプ、用途、疾患、地域によって区分されています。

“用途別では、治療薬分野がヒトマイクロバイオーム市場で最大のシェアを占める”
アプリケーションに基づき、ヒトマイクロバイオーム市場は治療薬、診断薬に分類されます。2023年には、マイクロバイオームがヒトの健康維持に果たす重要な役割に対する理解が進んでいることから、治療薬分野が市場を席巻します。また、製薬企業やバイオテクノロジー企業からの投資の増加や個別化医療に対する需要の高まりも市場を牽引しています。

“疾患別では感染症分野がヒトマイクロバイオーム市場で最大シェアを占める”
疾患別に見ると、ヒトマイクロバイオーム市場は感染症、内分泌・代謝疾患、消化器疾患、がん、その他の疾患に区分されます。2023年には、感染症分野がヒトマイクロバイオーム市場でより大きなシェアを占めます。この市場セグメントの成長は、ヒトの健康におけるマイクロバイオームの役割に対する理解が深まっていること、および高度なシーケンシング技術とバイオインフォマティクス技術の開発により、感染症の予防と治療のための新規マイクロバイオームベースの治療薬の発見と特性解析への道が開けていることに起因しています。
 
“北米：ヒトマイクロバイオーム市場で最大のシェア”
ヒトマイクロバイオーム市場で最大のシェアを占めたのは北米です。北米地域の大きなシェアは、高度なインフラ、最先端の研究機関、マイクロバイオーム研究を専門とするバイオテクノロジー企業やCROの強力なエコシステムなど、同地域で確立されたヘルスケアおよびバイオテクノロジー産業に起因しています。北米には、マイクロバイオーム研究に特化したプログラムや専門知識を有する一流の学術機関、研究病院、民間企業が存在することが、ヒトマイクロバイオーム市場の成長に寄与しています。

“アジア太平洋地域： ヒトマイクロバイオーム市場で最も急成長している地域”
アジア太平洋地域のヒトマイクロバイオーム市場は、予測期間中に最も高いCAGRで成長すると予測されています。この背景には、健康と疾患におけるマイクロバイオームの重要性に対する認識の高まり、個別化医療に対する需要の高まり、シーケンス技術の進歩があります。アジア太平洋地域のヒトマイクロバイオーム市場のもう一つの主要な促進要因は、同地域の人口の多さと急速な高齢化です。

本レポートのために実施した一次インタビューは以下のように分類できます：
– 回答者別 供給側60％、需要側40％、リサーチサイエンティスト30％、マネージャー30％
– 国別 北米22%、欧州42%、アジア太平洋地域11%、その他の地域25％

著名プレイヤー
• Seres Therapeutics, Inc. (US)
• Enterome (France)
• 4D pharma plc (UK)
• International Flavors & Fragrances Inc. (US)
• OptiBiotix Health Plc (UK)
• Ferring Pharmaceuticals (Switzerland)
• Synlogic, Inc. (US)
• Second Genome, Inc. (US)
• Vedanta Biosciences, Inc. (US)
• YSOPIA Bioscience (France)
• FlightPath Biosciences, Inc. (US)
• Finch Therapeutics Group, Inc. (US)
• AOBiome Therapeutics (US)
• BioGaia (Sweden)
• Quantbiome, Inc. (dba Ombre) (US)
• Viome Life Sciences, Inc. (US)
• BIOHM Health (US)
• DayTwo (US)
• Atlas Biomed (UK)
• Bione Ventures Private Limited (India)
• Luxia Scientific (France)
• Metabiomics (US)
• Sun Genomics (US)
• Seed Health (US)
• Gnubiotics Sciences (Switzerland)

調査範囲
本レポートは、ヒトマイクロバイオーム市場の詳細な情報を提供します。製品（医薬品、診断検査、プロバイオティクス、プレバイオティクス、その他の製品）、用途（治療、診断）、疾患（感染症、消化器疾患、内分泌・代謝疾患、癌、その他の疾患）、タイプ（細菌コンソーシアム移植（BCT）/糞便微生物叢移植（FMT）、ペプチド、生きたバイオ治療製品、その他のタイプ）、地域（北米、欧州、アジア太平洋地域、その他の地域）など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、ヒトマイクロバイオーム市場全体とそのセグメントの売上高に最も近い概算値を提供することで、市場リーダー／新規参入者を支援します。また、ステークホルダーが競合状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場動向を理解し、主要な市場促進要因、阻害要因、動向、機会、および課題に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します。
– ヒトマイクロバイオーム市場の成長に影響を与える主要な促進要因（マイクロバイオーム研究のためのマイクロバイオーム産業と学界の協力的取り組み、個別化医療に対する需要の急増、ヒトマイクロバイオームの重要性に対する意識の高まり）、阻害要因（マイクロバイオームの商業化に対する複雑な規制政策の悪影響）、 機会（新たなマイクロバイオーム技術に取り組むために連携する主要企業や革新的な小規模企業の増加、シーケンスおよびバイオインフォマティクスの進歩）、および課題（マイクロバイオームベースの治療法の患者採用率の低さ、マイクロバイオーム治療法の開発に伴う複雑さ）分析。
– 製品開発／イノベーション： ヒトマイクロバイオーム市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察。
– 市場開発： 有利な市場に関する包括的な情報-本レポートでは、様々な地域にわたるヒトマイクロバイオーム市場を分析。
– 市場の多様化： ヒトマイクロバイオーム市場における新製品、未開拓の地域、最近の開発、投資に関する詳細な情報。
– 競合評価： Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), and OptiBiotix Health Plc (UK)など、ヒトマイクロバイオーム市場戦略における主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。

❖ レポートの目次 ❖

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS & EXCLUSIONS 25
1.3 STUDY SCOPE 26
1.4 YEARS CONSIDERED 26
1.5 CURRENCY 27
1.6 RESEARCH LIMITATIONS 27
1.7 STAKEHOLDERS 27
1.7.1 RECESSION IMPACT 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 1 HUMAN MICROBIOME MARKET: RESEARCH DESIGN 28
2.1.1 SECONDARY DATA 29
2.1.2 PRIMARY DATA 29
FIGURE 2 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES 30
2.2 MARKET ESTIMATION METHODOLOGY 30
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 31
FIGURE 4 HUMAN MICROBIOME MARKET SIZE, 2023 (USD MILLION) 32
FIGURE 5 HUMAN MICROBIOME MARKET: FINAL CAGR PROJECTIONS (2023−2029) 32
FIGURE 6 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 33
2.3 MARKET DATA ESTIMATION AND TRIANGULATION 34
2.3.1 DATA TRIANGULATION 34
FIGURE 7 DATA TRIANGULATION METHODOLOGY 34
2.4 INDUSTRY INSIGHTS 35
2.5 RESEARCH ASSUMPTIONS 35
2.6 HUMAN MICROBIOME MARKET: GLOBAL RECESSION IMPACT 36
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 36
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 36
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 36
3 EXECUTIVE SUMMARY 38
FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION) 38
FIGURE 9 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION) 39

FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION) 39
FIGURE 11 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT 40
4 PREMIUM INSIGHTS 41
4.1 HUMAN MICROBIOME MARKET OVERVIEW 41
FIGURE 12 RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH 41
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION AND COUNTRY (2023) 41
FIGURE 13 THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023 41
4.3 HUMAN MICROBIOME MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 42
FIGURE 14 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS 44
5.2.1 DRIVERS 44
5.2.1.1 Collaborative efforts between microbiome industry and academia for microbiome research 44
5.2.1.2 Surging demand for personalized medicine 45
5.2.1.3 Rising awareness about importance of human microbiome 45
5.2.2 RESTRAINTS 46
5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes 46
5.2.3 OPPORTUNITIES 46
5.2.3.1 Increased collaboration of key players and small innovative companies to work on new microbiome technologies 46
TABLE 5 EXAMPLES OF COMPANY DEVELOPMENT 47
5.2.4 CHALLENGES 48
5.2.4.1 Slow patient adoption of microbiome-based therapies 48
5.2.4.2 Complexities involved in development of microbiome therapies 48
5.3 TECHNOLOGY ANALYSIS 49
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 51
FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 51
5.5 SUPPLY AND VALUE CHAIN ANALYSIS 52
5.5.1 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS 52
FIGURE 17 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS 52
5.5.2 VALUE CHAIN ANALYSIS OF HUMAN MICROBIOME MARKET 53
FIGURE 18 HUMAN MICROBIOME MARKET: VALUE CHAIN ANALYSIS 53
5.6 ECOSYSTEM ANALYSIS 54
FIGURE 19 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS 54
5.7 PORTER’S FIVE FORCES ANALYSIS 54
TABLE 6 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS 54
5.7.1 THREAT OF NEW ENTRANTS 54
5.7.2 THREAT OF SUBSTITUTES 54
5.7.3 BARGAINING POWER OF BUYERS 55
5.7.4 BARGAINING POWER OF SUPPLIERS 55
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 55
5.8 REGULATORY ANALYSIS 56
5.8.1 FDA APPROVALS 56
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
5.9 PRICING ANALYSIS 58
TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT 58
5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS 58
5.10 KEY CONFERENCES AND EVENTS IN 2023 59
5.10.1 HUMAN MICROBIOME CONFERENCES (2023) 59
TABLE 12 HUMAN MICROBIOME CONFERENCES (2023) 59
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 60
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 60
FIGURE 20 HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 60
5.11.2 HUMAN MICROBIOME MARKET: BUYING CRITERIA 60
FIGURE 21 KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS 60
6 HUMAN MICROBIOME MARKET, BY APPLICATION 61
6.1 INTRODUCTION 62
TABLE 13 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 62
6.2 THERAPEUTICS 62
6.2.1 AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET 62
TABLE 14 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023–2029 (USD MILLION) 64
TABLE 15 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION) 64
TABLE 16 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION) 64
TABLE 17 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION) 65
6.3 DIAGNOSTICS 65
6.3.1 INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET 65
TABLE 18 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023–2029 (USD MILLION) 66
TABLE 19 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION) 66
TABLE 20 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION) 67
TABLE 21 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION) 67
7 HUMAN MICROBIOME MARKET, BY DISEASE 68
7.1 INTRODUCTION 69
TABLE 22 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 69
7.2 INFECTIOUS DISEASES 69
7.2.1 RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET 69
TABLE 23 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES 70
TABLE 24 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2029 (USD MILLION) 71
TABLE 25 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 71
TABLE 26 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 71
TABLE 27 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 72
7.3 GASTROINTESTINAL DISEASES 72
7.3.1 SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET 72
TABLE 28 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2029 (USD MILLION) 72
TABLE 29 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 73
TABLE 30 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 73
TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 73
7.4 ENDOCRINE & METABOLIC DISORDERS 74
7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET 74
TABLE 32 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS 74
TABLE 33 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION) 75
TABLE 34 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 75
TABLE 35 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 75
TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 76
7.5 CANCER 76
7.5.1 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET 76
TABLE 37 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023–2029 (USD MILLION) 77
TABLE 38 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 77
TABLE 39 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 77
TABLE 40 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 78
7.6 OTHER DISEASES 78
TABLE 41 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2029 (USD MILLION) 78
TABLE 42 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 78
TABLE 43 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 79
TABLE 44 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 79
8 HUMAN MICROBIOME MARKET, BY PRODUCT 80
8.1 INTRODUCTION 81
TABLE 45 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)) 81
8.2 DRUGS 81
8.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET 81
TABLE 46 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023–2029 (USD MILLION) 82
TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 82
TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 82
TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 83
8.3 DIAGNOSTIC TESTS 83
8.3.1 GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET 83
TABLE 50 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023–2029 (USD MILLION) 84
TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 84
TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 85
TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 85
8.4 PROBIOTICS 85
8.4.1 GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY 85
TABLE 54 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023–2029 (USD MILLION) 86
TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 86
TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 87
TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 87
8.5 PREBIOTICS 87
8.5.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH 87
TABLE 58 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023–2029 (USD MILLION) 88
TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 88
TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 89
TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 89
8.6 OTHER PRODUCTS 89
TABLE 62 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2029 (USD MILLION) 90
TABLE 63 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 90
TABLE 64 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 90
TABLE 65 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 91
9 HUMAN MICROBIOME MARKET, BY TYPE 92
9.1 INTRODUCTION 93
TABLE 66 HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 93
9.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) 93
9.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH 93
TABLE 67 HUMAN MICROBIOME MARKET FOR BCT/FMT, BY REGION, 2023–2029 (USD MILLION) 94
TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION) 94
TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION) 94
TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION) 95
9.3 PEPTIDES 95
9.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET 95
TABLE 71 HUMAN MICROBIOME MARKET FOR PEPTIDES, BY REGION, 2023–2029 (USD MILLION) 96
TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION) 96
TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION) 96
TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION) 97
9.4 LIVE BIOTHERAPEUTIC PRODUCTS 97
9.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET 97
TABLE 75 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023–2029 (USD MILLION) 98
TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 98
TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 98
TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 99
9.5 OTHER TYPES 99
TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY REGION, 2023–2029 (USD MILLION) 99
TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION) 100
TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION) 100
TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION) 100
10 HUMAN MICROBIOME MARKET, BY REGION 101
10.1 INTRODUCTION 102
FIGURE 22 HUMAN MICROBIOME MARKET, BY REGION, 2023 VS. 2029 (USD MILLION) 102
TABLE 83 HUMAN MICROBIOME MARKET, BY REGION, 2023–2029 (USD MILLION) 102
10.2 NORTH AMERICA 103
FIGURE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT 104
TABLE 84 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 104
TABLE 85 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 105
TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 105
TABLE 87 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 105
10.2.1 US 106
10.2.1.1 Spike in research activities to drive market 106
TABLE 88 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 106
TABLE 89 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 107
TABLE 90 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 107
TABLE 91 US: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 107
10.2.2 CANADA 108
10.2.2.1 Rising prevalence of chronic diseases to boost microbiome research 108
TABLE 92 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 108
TABLE 93 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 108
TABLE 94 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 109
TABLE 95 CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 109
10.2.3 NORTH AMERICA: RECESSION IMPACT 109
10.3 EUROPE 110
TABLE 96 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 110
TABLE 97 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 111
TABLE 98 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 111
TABLE 99 EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 111
10.3.1 GERMANY 112
10.3.1.1 Rapid increase in government funding to propel market 112
TABLE 100 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 112
TABLE 101 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 112
TABLE 102 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 113
TABLE 103 GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 113
10.3.2 UK 113
10.3.2.1 Significant government investments in genomics research to propel growth 113
TABLE 104 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 114
TABLE 105 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 114
TABLE 106 UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 114
TABLE 107 UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 115
10.3.3 FRANCE 115
10.3.3.1 Rise in microbiome sequencing startups to boost growth 115
TABLE 108 HUMAN MICROBIOME STARTUPS IN FRANCE 116
TABLE 109 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 116
TABLE 110 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 117
TABLE 111 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 117
TABLE 112 FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 117
10.3.4 REST OF EUROPE 118
TABLE 113 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 118
TABLE 114 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 118
TABLE 115 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 119
TABLE 116 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 119
10.3.5 EUROPE: IMPACT OF RECESSION 119
10.4 ASIA PACIFIC 120
FIGURE 24 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT 121
TABLE 117 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2029 (USD MILLION) 121
TABLE 118 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 122
TABLE 119 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 122
TABLE 120 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 122
TABLE 121 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 123
10.4.1 CHINA 123
10.4.1.1 Increasing R&D investments to drive growth 123
TABLE 122 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 124
TABLE 123 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 124
TABLE 124 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 124
TABLE 125 CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 125

10.4.2 JAPAN 125
10.4.2.1 Growing geriatric population to present opportunities for market growth 125
TABLE 126 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 126
TABLE 127 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 126
TABLE 128 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 126
TABLE 129 JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 127
10.4.3 INDIA 127
10.4.3.1 Increasing prevalence of chronic diseases to support growth 127
TABLE 130 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 128
TABLE 131 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 128
TABLE 132 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 128
TABLE 133 INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 129
10.4.4 REST OF ASIA PACIFIC 129
TABLE 134 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 129
TABLE 135 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 130
TABLE 136 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 130
TABLE 137 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 130
10.4.5 ASIA PACIFIC: RECESSION IMPACT 131
10.5 REST OF THE WORLD 131
TABLE 138 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 131
TABLE 139 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 132
TABLE 140 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 132
TABLE 141 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 132
10.5.1 REST OF THE WORLD: RECESSION IMPACT 133
11 COMPETITIVE LANDSCAPE 134
11.1 INTRODUCTION 134
11.2 KEY STRATEGIES ADOPTED BY PLAYERS 134
FIGURE 25 HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 135

11.3 COMPANY EVALUATION QUADRANT 136
FIGURE 26 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (2022) 137
11.3.1 STARS 138
11.3.2 EMERGING LEADERS 138
11.3.3 PERVASIVE PLAYERS 138
11.3.4 PARTICIPANTS 138
11.4 COMPANY EVALUATION QUADRANT: START-UPS/SMES 139
11.4.1 PROGRESSIVE COMPANIES 139
11.4.2 STARTING BLOCKS 139
11.4.3 RESPONSIVE COMPANIES 139
11.4.4 DYNAMIC COMPANIES 139
FIGURE 27 HUMAN MICROBIOME MARKET: START-UPS/SMES EVALUATION QUADRANT (2022) 140
11.4.5 COMPETITIVE BENCHMARKING 141
11.4.5.1 Human microbiome market: Detailed list of start-ups/SMEs 141
TABLE 142 HUMAN MICROBIOME MARKET: DETAILED LIST OF START-UPS/SMES 141
11.4.5.2 Human microbiome market: Competitive benchmarking of key players (start-ups/SMEs) 142
TABLE 143 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES) 142
11.5 COMPETITIVE SCENARIO AND TRENDS 142
TABLE 144 HUMAN MICROBIOME MARKET: DEALS 142
11.5.1 PRODUCT LAUNCHES 144
TABLE 145 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES 144
11.5.2 EXPANSIONS 144
TABLE 146 HUMAN MICROBIOME MARKET: EXPANSIONS 144
12 COMPANY PROFILES 145
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS 145
12.1.1 SERES THERAPEUTICS, INC. 145
TABLE 147 SERES THERAPEUTICS, INC.: COMPANY OVERVIEW 145
12.1.2 ENTEROME 148
TABLE 148 ENTEROME: COMPANY OVERVIEW 148
12.1.3 4D PHARMA PLC 151
TABLE 149 4D PHARMA: COMPANY OVERVIEW 151
FIGURE 29 4D PHARMA: COMPANY SNAPSHOT (2022) 151
12.1.4 INTERNATIONAL FLAVORS & FRAGRANCES, INC. 154
TABLE 150 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW 154
FIGURE 30 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022) 155

12.1.5 OPTIBIOTIX HEALTH PLC 157
TABLE 151 OPTIBIOTIX: COMPANY OVERVIEW 157
FIGURE 31 OPTIBIOTIX: COMPANY SNAPSHOT (2021) 158
12.1.6 FERRING PHARMACEUTICALS 162
TABLE 152 FERRING PHARMACEUTICALS: COMPANY OVERVIEW 162
12.1.7 SYNLOGIC, INC. 163
TABLE 153 SYNLOGIC, INC.: COMPANY OVERVIEW 163
FIGURE 32 SYNLOGIC, INC: COMPANY SNAPSHOT (2022) 163
12.1.8 SECOND GENOME INC. 165
TABLE 154 SECOND GENOME INC.: COMPANY OVERVIEW 165
12.1.9 VEDANTA BIOSCIENCES, INC. 167
TABLE 155 VEDANTA BIOSCIENCES: COMPANY OVERVIEW 167
12.1.10 YSOPIA BIOSCIENCE 169
TABLE 156 YSOPIA BIOSCIENCE: COMPANY OVERVIEW 169
12.1.11 FLIGHTPATH BIOSCIENCES, INC. 170
TABLE 157 FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW 170
12.1.12 FINCH THERAPEUTICS GROUP, INC. 171
TABLE 158 FINCH THERAPEUTICS: COMPANY OVERVIEW 171
FIGURE 33 FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022) 171
12.1.13 AOBIOME THERAPEUTICS 172
TABLE 159 AOBIOME THERAPEUTICS: COMPANY OVERVIEW 172
12.1.14 BIOGAIA 173
TABLE 160 BIOGAIA: COMPANY OVERVIEW 173
FIGURE 34 BIOGAIA: COMPANY SNAPSHOT (2021) 174
12.1.15 QUANTBIOME, INC. (DBA OMBRE) 177
TABLE 161 QUANTBIOME, INC.: COMPANY OVERVIEW 177
12.2 OTHER PLAYERS 178
12.2.1 VIOME LIFE SCIENCES, INC. 178
12.2.2 BIOHM HEALTH 178
12.2.3 DAYTWO 179
12.2.4 ALTAS BIOMED 179
12.2.5 BIONE VENTURES PRIVATE LIMITED 180
12.2.6 LUXIA SCIENTIFIC 180
12.2.7 METABIOMICS 181
12.2.8 SUN GENOMICS 181
12.2.9 SEED HEALTH 182
12.2.10 GNUBIOTICS SCIENCES 182
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX 183
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 186
13.2 CUSTOMIZATION OPTIONS 188
13.3 RELATED REPORTS 188
13.4 AUTHOR DETAILS 189



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ ヒトマイクロバイオームの世界市場予測（〜2029年）：製品別、用途別、疾患別、種類別(Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • ヒトマイクロバイオームの世界市場予測（～2030）

    • ◆H&Iグローバルリサーチのお客様（例）◆